Reuters

(Reuters) - U.S. stock index futures advanced on Thursday, a day after the Federal Reserve left interest rates unchanged and allayed fears around potential rate hikes, with focus moving to a spate of earnings updates through the day.

While Fed chair Jerome Powell indicated that stubbornly high inflation would see a long-expected U.S. rate cut pushed back, he refused to entertain talk that rates might actually need to go up again.

Money... (continue reading...)

By Patrick Wingrove

(Reuters) - Moderna on Thursday reported quarterly revenue that beat Wall Street estimates but came in dramatically lower than the previous year when demand for COVID-19 vaccines was higher.

Sales of Moderna’s COVID-19 shot Spikevax, its only marketed product, dropped 91% from the previous year to $167 million for the quarter but surpassed analysts’ expectations of $97.5 million.

The Cambridge,... (continue reading...)

By Chibuike Oguh

NEW YORK (Reuters) - Apollo Global Management said on Thursday its first-quarter adjusted net income rose 26% year-on-year, driven mostly by growth in management fees as well as earnings from its flagship annuities business.

Adjust net income rose to $1.1 billion, up from $825 million a year earlier. That translated to adjusted net income per share of $1.72, which came in slightly lower than the average Wall Street... (continue reading...)

Thomson Reuters beat revenue expectations and raised its annual financial forecast on Thursday as it continued to invest heavily in artificial intelligence.

The Toronto-based news and information provider reported first quarter revenue up 8% to $1.88 billion, from $1.74 billion a year earlier. Wall Street expected $1.85 billion in the quarter, according to LSEG.

Operating profit, which rose 10% to $557 million, fell short of expectations of... (continue reading...)

(Reuters) -U.S. drugmaker Regeneron Pharmaceuticals Inc missed Wall Street estimates for first-quarter profit on Thursday due to softer sales of its blockbuster eye drug Eylea and its eczema treatment, Dupixent.

Excluding items, the company reported a profit of $9.55 per share for the quarter, compared with analysts' estimates of $10.09 per share, according to LSEG data.

Regeneron has been looking to switch Eylea patients to the high-dose... (continue reading...)